NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
Clinical Trials
44 trialsNCT05868915 2026-01-21
HV-101 for Patients With Advanced Solid Tumors
Hervor Therapeutics
Phase 1 Terminated
NCT03968653 2025-12-05
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT03522142 2025-10-09
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Incyte Corporation
Phase 1 Terminated
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT03387917 2024-12-02
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
Phase 1 Terminated
NCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
NCT02994953 2024-09-20
COMBO
EMD Serono
Phase 1 Terminated
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT05430555 2024-02-07
IMAG1NE
T-knife GmbH
Phase 1/2 Terminated
NCT03954704 2023-11-21
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT05470933 2023-09-01
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
Phase 1 Terminated
NCT04601285 2023-07-06
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT04746612 2023-03-30
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT05010525 2023-03-17
REACH
Antengene Corporation
Phase 1/2 Terminated
NCT04518137 2023-01-31
A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
Antengene Corporation
Phase 2 Terminated
NCT04735796 2022-10-26
Study of LM-102 in Subjects in Advanced Tumors
LaNova Medicines Limited
Phase 1 Terminated
NCT04049617 2022-10-06
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT05008913 2022-09-06
ADME
AstraZeneca
Phase 1 Terminated
NCT03665129 2022-01-27
STELLAR-001
Innate Pharma
Phase 1 Terminated
NCT01433991 2021-06-08
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Eisai Inc.
Phase 1/2 Terminated
NCT01529307 2020-12-21
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT01064089 2020-12-08
Dose Escalation of HSP990 in Japan/Korea
Novartis
Phase 1 Terminated
NCT03256331 2020-06-01
Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
Belx Bio-Pharmaceutical (Taiwan) Corporation
Phase 1 Terminated
NCT03700294 2020-05-01
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT01163071 2019-11-14
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
Celgene
Phase 1 Terminated
NCT03065023 2019-07-30
MK-4621-001
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT03320525 2018-10-02
CHITIN
Herlev Hospital
Phase 1 Terminated
NCT02243917 2018-02-27
A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
Cleave Biosciences, Inc.
Phase 1 Terminated
NCT02040558 2017-04-05
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
Mallinckrodt
Phase 1 Terminated
NCT00359671 2016-11-29
Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00632424 2016-03-10
Phase 1 Trial of Oral Ixabepilone
R-Pharm
Phase 1 Terminated
NCT01497626 2016-02-17
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Phase 1 Terminated
NCT01004822 2015-11-20
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00932126 2015-10-28
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00546247 2015-10-12
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00550017 2015-10-12
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00951158 2015-05-12
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Terminated
NCT01286974 2012-09-21
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
Abbott
Phase 1 Terminated
NCT01016327 2012-09-07
Study of NMS-1116354 in Solid Tumors
Nerviano Medical Sciences
Phase 1 Terminated